Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Eli Lilly announced that its breakthrough drug, Mounjaro (tirzepatide), has received marketing authorization from India’s ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Disclosures: Garg reports consulting for Abbott Diabetes Care, Eli Lilly, Medtronic, Novo Nordisk, Roche and Zealand and receiving research grants through the University of Colorado from Dexcom ...

Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal to $1.3 billion, The WSJ reported.

Eli Lilly and Company (NYSE:LLY) was the only pharmaceutical company to make the list. The firm offers a dividend yield of 0.76% and has seen its stock has surged by nearly 2% year-to-date.

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billion Verve is developing a one-time gene-editing treatment for heart disease The company's lead drug, Verve-102, targets a gene linked ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billion Verve is developing a one-time gene-editing treatment for heart disease The company's lead drug, Verve-102, targets a gene linked to ...